KLRA
Kailera Therapeutics, Inc. (NASDAQ)
Healthcare — Biotechnology
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
Price History
Fundamentals
| Market Cap | $2.70B |
| P/E Ratio (TTM) | - |
| Forward P/E | -5.58 |
| EPS (TTM) | $-1.78 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | - |
| Debt/Equity | 1.87 |
| Recommendation | Strong Buy 1.2 |
| Analyst Target | $42.60 |
| Analysts | 5 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 57.0 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $28.23 |
| 52-Week Low | $18.50 |
| 50-Day Avg | $21.83 |
| 200-Day Avg | $21.96 |
| Avg Volume | 981.3K |
| Volume | $1.20M |
Performance Analysis
BULLISHKLRA shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:17 UTC
Back to Screener Export Report